NPPA and cardiomyopathy: The literature shows that proteasome inhibition alleviates cardiomyopathy by improving left ventricular function via the upregulation of atrial natriuretic peptide (ANP), β myosin heavy chain and NRF-2 expression [19] and reduces myocardial infarct size by regulating inflammation, autophagy and antioxidant activity [20].